Daniel Whitehurst, William Otto, Bethany Verkamp, Grant Paulsen, Lara Danziger-Isakov, Hilary Miller-Handley
{"title":"Clinical Impact of Bronchoalveolar Lavage in Pediatric and Young Adult Patients With Cancer and Suspected Respiratory Infections.","authors":"Daniel Whitehurst, William Otto, Bethany Verkamp, Grant Paulsen, Lara Danziger-Isakov, Hilary Miller-Handley","doi":"10.1093/jpids/piae124","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Respiratory infections cause a significant amount of morbidity and mortality in pediatric and young adult patients with malignancy. Bronchoscopy with bronchoalveolar lavage (BAL) is frequently utilized in the diagnostic process, but which patients would most benefit is poorly understood.</p><p><strong>Methods: </strong>A retrospective study from 2013 to 2022 examined patients with active malignancy who underwent bronchoscopy with BAL. Positive and negative clinical impacts were assessed by 3 independent reviewers according to predetermined criteria. Mixed-effects logistic regression was performed to identify factors associated with positive and negative clinical impact.</p><p><strong>Results: </strong>In total, 145 bronchoscopies met inclusion criteria with a median patient age of 12 years (interquartile range 5-17). A total of 30.3% of bronchoscopies had a positive clinical impact with 17.2% leading to a new diagnosis, most commonly Pneumocystis jirovecii pneumonia (PJP) (7.6%). Comparatively, 18.6% had a negative clinical impact, most commonly from a procedural complication (13.1%). Trimethoprim-sulfamethoxazole (TMP-SMX) initiation for treatment of suspected PJP prior to BAL (adjusted odds ratio [aOR] 11.20, 95% CI 1.32-95.29) was associated with positive clinical impact. Requirement for ICU-level care (aOR 18.85, 95% CI 3.60-98.69) or oxygen supplementation by nasal cannula prior to BAL (aOR 18.41, 95% CI 4.78-70.95) were associated with negative clinical impact while prior invasive ventilation (aOR 0.09, 95% CI 0.01-0.58) was associated with the absence of negative clinical impact.</p><p><strong>Conclusions: </strong>Patients with potential respiratory infections with high clinical suspicion for PJP who had been started on treatment TMP-SMX prior to BAL benefit most from bronchoscopy with BAL. Patients intubated prior to BAL who were deemed clinically safe for bronchoscopy tolerated the procedure better than those in the ICU not requiring intubation or those requiring supplemental oxygen via nasal cannula.</p>","PeriodicalId":17374,"journal":{"name":"Journal of the Pediatric Infectious Diseases Society","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of the Pediatric Infectious Diseases Society","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jpids/piae124","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Respiratory infections cause a significant amount of morbidity and mortality in pediatric and young adult patients with malignancy. Bronchoscopy with bronchoalveolar lavage (BAL) is frequently utilized in the diagnostic process, but which patients would most benefit is poorly understood.
Methods: A retrospective study from 2013 to 2022 examined patients with active malignancy who underwent bronchoscopy with BAL. Positive and negative clinical impacts were assessed by 3 independent reviewers according to predetermined criteria. Mixed-effects logistic regression was performed to identify factors associated with positive and negative clinical impact.
Results: In total, 145 bronchoscopies met inclusion criteria with a median patient age of 12 years (interquartile range 5-17). A total of 30.3% of bronchoscopies had a positive clinical impact with 17.2% leading to a new diagnosis, most commonly Pneumocystis jirovecii pneumonia (PJP) (7.6%). Comparatively, 18.6% had a negative clinical impact, most commonly from a procedural complication (13.1%). Trimethoprim-sulfamethoxazole (TMP-SMX) initiation for treatment of suspected PJP prior to BAL (adjusted odds ratio [aOR] 11.20, 95% CI 1.32-95.29) was associated with positive clinical impact. Requirement for ICU-level care (aOR 18.85, 95% CI 3.60-98.69) or oxygen supplementation by nasal cannula prior to BAL (aOR 18.41, 95% CI 4.78-70.95) were associated with negative clinical impact while prior invasive ventilation (aOR 0.09, 95% CI 0.01-0.58) was associated with the absence of negative clinical impact.
Conclusions: Patients with potential respiratory infections with high clinical suspicion for PJP who had been started on treatment TMP-SMX prior to BAL benefit most from bronchoscopy with BAL. Patients intubated prior to BAL who were deemed clinically safe for bronchoscopy tolerated the procedure better than those in the ICU not requiring intubation or those requiring supplemental oxygen via nasal cannula.
背景:呼吸道感染在儿童和青年恶性肿瘤患者中引起大量的发病率和死亡率。支气管镜检查与支气管肺泡灌洗(BAL)在诊断过程中经常使用,但哪些患者最受益尚不清楚。方法:2013-2022年的一项回顾性研究检查了行支气管镜检查BAL的活动性恶性肿瘤患者。正面和负面临床影响由三名独立审稿人根据预先确定的标准进行评估。采用混合效应逻辑回归来确定与积极和消极临床影响相关的因素。结果:145例支气管镜检查符合纳入标准,患者中位年龄为12岁(IQR 5-17)。30.3%的支气管镜检查有积极的临床影响,其中17.2%导致新诊断,最常见的是乙基肺囊虫肺炎(PJP)(7.6%)。相比之下,18.6%的患者有负面临床影响,最常见的是手术并发症(13.1%)。在BAL之前开始使用甲氧苄啶-磺胺甲恶唑治疗疑似PJP (aOR 11.20, 95% CI 1.32-95.29)与积极的临床影响相关。需要icu级护理(aOR 18.85, 95% CI 3.60-98.69)或BAL前鼻导管补氧(aOR 18.41, 95% CI 4.78-70.95)与负面临床影响相关,而先前的有创通气(aOR 0.09, 95% CI 0.01-0.58)与无负面临床影响相关。结论:临床高度怀疑PJP的潜在呼吸道感染患者在BAL前已开始使用甲氧苄氨嘧啶-磺胺甲恶唑治疗,支气管镜下BAL获益最多。先前插管的患者被认为是临床安全的支气管镜检查患者比在ICU中使用鼻插管的患者更能耐受该手术。
期刊介绍:
The Journal of the Pediatric Infectious Diseases Society (JPIDS), the official journal of the Pediatric Infectious Diseases Society, is dedicated to perinatal, childhood, and adolescent infectious diseases.
The journal is a high-quality source of original research articles, clinical trial reports, guidelines, and topical reviews, with particular attention to the interests and needs of the global pediatric infectious diseases communities.